MedPath
HSA Product

RELENZA ROTADISK 5 mg/dose

Product approved by Health Sciences Authority (SG)

Basic Information

RELENZA ROTADISK 5 mg/dose

POWDER, METERED

Regulatory Information

SIN11199P

October 21, 1999

Prescription Only

Therapeutic

RESPIRATORY (INHALATION)

August 10, 2023

June 3, 2025

XJ05AH01

Company Information

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Active Ingredients

ZANAMIVIR

Strength: 5 mg/dose

Detailed Information

Contraindications

**Contra-indications** Hypersensitivity to any ingredient of the preparation (see Pharmaceutical Particulars – List of Excipients – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Contraindicated in patients with severe milk protein allergy.

Indication Information

**Indications** Treatment of Influenza: Relenza is indicated for treatment of infections due to influenza A and B viruses in adults and children 5 years and older. Prophylaxis: Relenza is indicated for prophylaxis of both influenza A and B in adults and juveniles 12 years and older.

© Copyright 2025. All Rights Reserved by MedPath